NCT06433219 2026-02-18
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
EMD Serono
Phase 2 Active not recruiting
EMD Serono
EMD Serono
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany